Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 33, Issue 27, Pages 3008-U105Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2014.59.4648
Keywords
-
Categories
Funding
- Children's Oncology Group Chair [U10-CA98543]
- St Baldrick's Foundation
- National Institutes of Health Clinical Therapeutics Training Grant [T32GM007019]
- Cancer Research Foundation
- Alex's Lemonade Stand Foundation
- William Guy Forbeck Research Foundation
- Little Heroes Cancer Research Fund
- Children's Neuroblastoma Cancer Foundation
- Neuroblastoma Children's Cancer Foundation
- Staehely Foundation
- Super Jake Foundation
- Cancer Research UK Life Chair and Programme grant included in Cancer Research UK Institute of Cancer Research (ICR) Core Award [C347/A15403]
- National Institute for Health Research Royal Marsden/ICR Biomedical Research Centre
Ask authors/readers for more resources
Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in various institutional and cooperative groups were disparate, limiting the ability to compare clinical trial results. To mitigate this problem and enhance collaborative research, homogenous pretreatment patient cohorts have been defined by the International Neuroblastoma Risk Group classification system. During the past 30 years, increasingly intensive, multimodality approaches have been developed to treat patients who are classified as high risk, whereas patients with low- or intermediate-risk neuroblastoma have received reduced therapy. This treatment approach has resulted in improved outcome, although survival for high-risk patients remains poor, emphasizing the need for more effective treatments. Increased knowledge regarding the biology and genetic basis of neuroblastoma has led to the discovery of druggable targets and promising, new therapeutic approaches. Collaborative efforts of institutions and international cooperative groups have led to advances in our understanding of neuroblastoma biology, refinements in risk classification, and stratified treatment strategies, resulting in improved outcome. International collaboration will be even more critical when evaluating therapies designed to treat small cohorts of patients with rare actionable mutations. (C) 2015 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available